|
|
7470 W. Chandler Blvd.
Chandler, AZ 85226 USA
phone:480.755.9483
fax:480.755.9832
|
|
| Symbol |
Private |
| Founded |
1995 |
| Employees |
|
|
|
| www.sensysmedical.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Researches and develops a non-invasive medical device to measure blood glucose levels for diabetes management. |
|
| Management |
| Robert E. Curry, Ph.D., Chairman, Chief Executive Officer; Stephen L. Monfre, Ph.D., Chief Operating Officer; Tammie J. Woolgar, CPA, VP of Administration, Controller; Linda J. Hockersmith, RD, CDE, VP of Clinical & Regulatory Affairs |
| |
|
|
| |
|
| Keywords |
| Diabetes, blood sugar, diabetic, metabolic, insulin, blood glucose, medical device, device, advamed |
|
|
|
| Description |
|
Sensys Medical is committed to advancing blood glucose monitoring and the science of diabetes disease management through the creation and commercialization of the Sensys Glucose Tracking System (Sensys GTS'), a non-invasive blood glucose measurement device.
|
|
| Products / Services |
The Sensys Glucose Tracking System (Sensys GTS') enables people living with diabetes to conduct unlimited testing of blood glucose levels and to track these levels over time to better understand the effect of medication, meals, exercise and state of health.
|
|
| Technology / Differentiation |
| Uses NIR-DRS as the process of understanding how NIR light (750-2500nm) interacts with various molecules (e.g. fat, glucose, protein, and water) in human tissue. Each type of molecule reacts differently (i.e. absorbs NIR light) when illuminated with NIR light. The amount of light absorbed is proportional to the concentration of that particular molecule. NIR-DRS has an inherent advantage due to its non-destructive and fast nature.
|
|
| Market / Customers |
According to a 2005 report from the Centers for Disease Control and Prevention, an estimated 20.8 million Americans have diabetes. This figure represents a 14% increase in only two years. In addition, in the year 2002 The American Diabetes Association estimated that the total costs of diabetes (including indirect costs) was more than $132 billion.
|
|
| Funding |
| Current investors include: Alliance Technology Ventures, A.M. Pappas and Associates, AIM Investments, Adams Street Partners, and Adams Capital Management. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members